In brief
Kalundborg, home to Wegovy's production, has seen a £6 billion investment but struggles with low population retention and underfunded schools. Can the town evolve beyond its "Novo Queue"?
Kalundborg, a cozy Danish town of just 16,000 residents, has become the focal point of a modern-day financial boom due to investment from Novo Nordisk. With over £6 billion poured into this small coastal town, which produces the popular weight loss drug Wegovy, you'd expect a flourishing community. However, the reality is more complex. While factory workers flood in each morning, they rarely stay, contributing to a daily “Novo Queue” traffic jam. Many locals prefer to drive from larger cities for a better lifestyle, causing frustration among residents, who call the town boring. Despite the influx of cash, Kalundborg struggles with enduring issues such as low-income families, rundown schools, and a concerning rate of childhood obesity—ranked in the top 5% in Denmark for this problem.Though the Novo Nordisk factory is the heart of economic activity, local businesses face challenges. Shops catering to factory workers often fail quickly due to lack of permanent residents. The mayor remains optimistic, citing job creation and improvements in local facilities, indicating a hopeful outlook for the future.Young residents express mixed feelings about their town's potential. While some students wish to leave for larger cities, others see promise in Kalundborg evolving into a multicultural hub. With upcoming infrastructure improvements, the challenge lies in attracting people to not just work, but live in the town, forging a sustainable future for this evolving Danish community.
